Detail akcie AVAX Tech online

Business Summary: AVAX Technologies, Inc. is a biotechnology company. The Company is focused on developing and commercializing its Autologous Cell (AC) Vaccine Technology Platform for the treatment of cancer. The AC Vaccine is a platform technology, which allows a patient's immune system to recognize its own cancer cells as foreign through the process of haptenization, cell processing and regimen of administration. The Company has approximately two vaccines that have completed Phase II clinical trials, both designated with Orphan Drug Status. MVAX is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage IV melanoma patients with measurable metastasis. OVAX is the Company's post-surgical autologous cell vaccine for Stage III and IV ovarian cancer. The OVAX trial is a Phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients.
Financial Summary: BRIEF: For the nine months ended 30 September 2008, AVAX Technologies Inc revenues increased 38% to $415K. Net loss increased 20% to $5.7M. Revenues reflect Gain from sale of the Product Product an increase of 34% to $402K, Grant revenue increase from $0K to $13K. Higher net loss reflects Interest Income decrease of 70% to $60K (income). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.04.